Superiority of AbCross enzyme-linked immunosorbent assay cross-match over the B-cell complement-dependent lymphocytotoxicity cross-match

P. Gombos, G. Opelz, S. Scherer, C. Morath, M. Zeier, P. Schemmer, R. Langer, C. Süsal

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: The AbCross enzyme-linked immunosorbent assay (ELISA) cross-match is a recently introduced solid phase cross-match technique with several technical advantages over the currently available Antibody Monitoring System ELISA cross-match. Methods: In the present study, we investigated the potential superiority of AbCross over the traditional complement-dependent lymphocytotoxicity (CDC) B-cell cross-match (BXM). Pretransplant sera of 271 kidney transplant recipients who were transplanted at our center between 1998 and 2010 were tested in ELISA screening for the presence of human leukocyte antigen (HLA) antibodies and in AbCross and CDC for antibody reactivity against solubilized donor HLA class I and II antigens and donor B cells, respectively. Results: Patients positive for HLA class I or II antibodies on ELISA screening had a significantly poorer graft outcome 2 years after transplantation than recipients who were negative for HLA antibodies (21% vs 6% graft loss; P =.002). Corresponding with this finding, 37 recipients positive for HLA antibodies in AbCross against donor HLA class I or II antigens had a 2-year post-transplant graft loss rate of 19%, which is significantly higher than the 8% rate in 186 recipients who were negative for both antibody classes in AbCross (P =.043). The 2-year graft loss rate in 34 AbCross positive but BXM negative patients was 21%, compared with 7% in 172 AbCross and BXM negative patients (P =.012) and 9% in 11 AbCross negative but BXM positive patients (P =.39). Conclusions: Our data indicate that the AbCross ELISA cross-match is superior to the CDC BXM, most likely because it detects antibodies against donor HLA antigens at a higher sensitivity.

Original languageEnglish
Pages (from-to)1383-1385
Number of pages3
JournalTransplantation Proceedings
Volume45
Issue number4
DOIs
Publication statusPublished - May 2013

Fingerprint

HLA Antigens
B-Lymphocytes
Enzyme-Linked Immunosorbent Assay
Antibodies
Transplants
Histocompatibility Antigens Class I
Histocompatibility Antigens Class II
Immunoglobulin Isotypes
Transplantation
Tissue Donors
Kidney
Antigens
Serum

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

Superiority of AbCross enzyme-linked immunosorbent assay cross-match over the B-cell complement-dependent lymphocytotoxicity cross-match. / Gombos, P.; Opelz, G.; Scherer, S.; Morath, C.; Zeier, M.; Schemmer, P.; Langer, R.; Süsal, C.

In: Transplantation Proceedings, Vol. 45, No. 4, 05.2013, p. 1383-1385.

Research output: Contribution to journalArticle

Gombos, P. ; Opelz, G. ; Scherer, S. ; Morath, C. ; Zeier, M. ; Schemmer, P. ; Langer, R. ; Süsal, C. / Superiority of AbCross enzyme-linked immunosorbent assay cross-match over the B-cell complement-dependent lymphocytotoxicity cross-match. In: Transplantation Proceedings. 2013 ; Vol. 45, No. 4. pp. 1383-1385.
@article{930c70fe432f4deb875d8ad5309ed1f8,
title = "Superiority of AbCross enzyme-linked immunosorbent assay cross-match over the B-cell complement-dependent lymphocytotoxicity cross-match",
abstract = "Background: The AbCross enzyme-linked immunosorbent assay (ELISA) cross-match is a recently introduced solid phase cross-match technique with several technical advantages over the currently available Antibody Monitoring System ELISA cross-match. Methods: In the present study, we investigated the potential superiority of AbCross over the traditional complement-dependent lymphocytotoxicity (CDC) B-cell cross-match (BXM). Pretransplant sera of 271 kidney transplant recipients who were transplanted at our center between 1998 and 2010 were tested in ELISA screening for the presence of human leukocyte antigen (HLA) antibodies and in AbCross and CDC for antibody reactivity against solubilized donor HLA class I and II antigens and donor B cells, respectively. Results: Patients positive for HLA class I or II antibodies on ELISA screening had a significantly poorer graft outcome 2 years after transplantation than recipients who were negative for HLA antibodies (21{\%} vs 6{\%} graft loss; P =.002). Corresponding with this finding, 37 recipients positive for HLA antibodies in AbCross against donor HLA class I or II antigens had a 2-year post-transplant graft loss rate of 19{\%}, which is significantly higher than the 8{\%} rate in 186 recipients who were negative for both antibody classes in AbCross (P =.043). The 2-year graft loss rate in 34 AbCross positive but BXM negative patients was 21{\%}, compared with 7{\%} in 172 AbCross and BXM negative patients (P =.012) and 9{\%} in 11 AbCross negative but BXM positive patients (P =.39). Conclusions: Our data indicate that the AbCross ELISA cross-match is superior to the CDC BXM, most likely because it detects antibodies against donor HLA antigens at a higher sensitivity.",
author = "P. Gombos and G. Opelz and S. Scherer and C. Morath and M. Zeier and P. Schemmer and R. Langer and C. S{\"u}sal",
year = "2013",
month = "5",
doi = "10.1016/j.transproceed.2013.01.039",
language = "English",
volume = "45",
pages = "1383--1385",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "4",

}

TY - JOUR

T1 - Superiority of AbCross enzyme-linked immunosorbent assay cross-match over the B-cell complement-dependent lymphocytotoxicity cross-match

AU - Gombos, P.

AU - Opelz, G.

AU - Scherer, S.

AU - Morath, C.

AU - Zeier, M.

AU - Schemmer, P.

AU - Langer, R.

AU - Süsal, C.

PY - 2013/5

Y1 - 2013/5

N2 - Background: The AbCross enzyme-linked immunosorbent assay (ELISA) cross-match is a recently introduced solid phase cross-match technique with several technical advantages over the currently available Antibody Monitoring System ELISA cross-match. Methods: In the present study, we investigated the potential superiority of AbCross over the traditional complement-dependent lymphocytotoxicity (CDC) B-cell cross-match (BXM). Pretransplant sera of 271 kidney transplant recipients who were transplanted at our center between 1998 and 2010 were tested in ELISA screening for the presence of human leukocyte antigen (HLA) antibodies and in AbCross and CDC for antibody reactivity against solubilized donor HLA class I and II antigens and donor B cells, respectively. Results: Patients positive for HLA class I or II antibodies on ELISA screening had a significantly poorer graft outcome 2 years after transplantation than recipients who were negative for HLA antibodies (21% vs 6% graft loss; P =.002). Corresponding with this finding, 37 recipients positive for HLA antibodies in AbCross against donor HLA class I or II antigens had a 2-year post-transplant graft loss rate of 19%, which is significantly higher than the 8% rate in 186 recipients who were negative for both antibody classes in AbCross (P =.043). The 2-year graft loss rate in 34 AbCross positive but BXM negative patients was 21%, compared with 7% in 172 AbCross and BXM negative patients (P =.012) and 9% in 11 AbCross negative but BXM positive patients (P =.39). Conclusions: Our data indicate that the AbCross ELISA cross-match is superior to the CDC BXM, most likely because it detects antibodies against donor HLA antigens at a higher sensitivity.

AB - Background: The AbCross enzyme-linked immunosorbent assay (ELISA) cross-match is a recently introduced solid phase cross-match technique with several technical advantages over the currently available Antibody Monitoring System ELISA cross-match. Methods: In the present study, we investigated the potential superiority of AbCross over the traditional complement-dependent lymphocytotoxicity (CDC) B-cell cross-match (BXM). Pretransplant sera of 271 kidney transplant recipients who were transplanted at our center between 1998 and 2010 were tested in ELISA screening for the presence of human leukocyte antigen (HLA) antibodies and in AbCross and CDC for antibody reactivity against solubilized donor HLA class I and II antigens and donor B cells, respectively. Results: Patients positive for HLA class I or II antibodies on ELISA screening had a significantly poorer graft outcome 2 years after transplantation than recipients who were negative for HLA antibodies (21% vs 6% graft loss; P =.002). Corresponding with this finding, 37 recipients positive for HLA antibodies in AbCross against donor HLA class I or II antigens had a 2-year post-transplant graft loss rate of 19%, which is significantly higher than the 8% rate in 186 recipients who were negative for both antibody classes in AbCross (P =.043). The 2-year graft loss rate in 34 AbCross positive but BXM negative patients was 21%, compared with 7% in 172 AbCross and BXM negative patients (P =.012) and 9% in 11 AbCross negative but BXM positive patients (P =.39). Conclusions: Our data indicate that the AbCross ELISA cross-match is superior to the CDC BXM, most likely because it detects antibodies against donor HLA antigens at a higher sensitivity.

UR - http://www.scopus.com/inward/record.url?scp=84878552428&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878552428&partnerID=8YFLogxK

U2 - 10.1016/j.transproceed.2013.01.039

DO - 10.1016/j.transproceed.2013.01.039

M3 - Article

VL - 45

SP - 1383

EP - 1385

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 4

ER -